AsymBio Breaks Ground on New Fengxian R&D Building

AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group, has broken ground on a new R&D building at the Shanghai Fengxian site. The project marks a pivotal infrastructure step in strengthening AsymBio’s biologics CDMO capabilities and reinforcing the Fengxian site’s role as a core development-and-manufacturing hub.

Full completion and official commissioning of the new eight-story building is slated for the second half of 2027. It will occupy approximately 2,500 square meters of land, provide nearly 20,000 square meters of gross floor area, and be constructed in full compliance with green and low-carbon construction standards. It will support cell line development, upstream and downstream process development, conjugation process development, drug product development, and comprehensive analytical development services.

Located adjacent to the clinical and commercial manufacturing facilities for antibodies and antibody-drug conjugates (ADCs), the building will serve as a dedicated R&D hub. Once operational, it will work in close alignment with the site’s production lines to streamline scale-up and commercial manufacturing while shortening overall project timelines.

The Fengxian R&D building will also provide the core physical carrier for the AccPCC (Accelerated PCC platform), an integrated R&D acceleration platform designed to shorten the development timeline from lead to preclinical candidate (PCC) selection. Built around an end-to-end, AI-enabled workflow, AccPCC connects early R&D and CMC with nonclinical evaluation and early clinical translation.

Rui Yang, CEO of AsymBio, said, “Effective biologics development requires earlier engagement, integrated scientific and CMC decision-making, and manufacturability considerations from the outset. By leveraging cross-site R&D resources across the entire Asymchem Group, AccPCC is designed to improve development efficiency, shorten the path to PCC selection and accelerate science-to-clinic translation. The Fengxian R&D building will be a key enabler of closer integration between early development, scale-up and manufacturing, helping clients reduce handoffs and manage complex programs with greater clarity, continuity and confidence.”